Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care

Mayo Clinic Proceedings

Volumn 76, Issue 3, 2001, Pages 299-309

  Rusnak, James M ^a   Kisabeth, Robert M ^b   Herbert, David P ^c   McNeil, Dennis M ^b  

^a Department of Internal Medicine ^*  (United States)

^b MAYO CLINIC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CAPTOPRIL; CLOZAPINE; CODEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIGOXIN; ENALAPRIL; FLUOROURACIL; HYDRALAZINE; IRINOTECAN; ISONIAZID; MERCAPTOPURINE; OMEPRAZOLE; PENICILLAMINE; PROGUANIL; SALBUTAMOL; SUXAMETHONIUM; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

ALZHEIMER DISEASE; APNEA; BLEEDING; CARDIOTOXICITY; DEPRESSION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; HYPOTENSION; LUPUS ERYTHEMATOSUS; MALARIA; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; PHARMACOGENOMICS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; STOMACH ULCER; XENOBIOTIC METABOLISM;

EID: 0035092089     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.3.299     Document Type: Article

References (83)

1. Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science. 1968;159:1479-1480.
2. Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science. 1968;161:72-73.
3. Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest. 1968;47:2657-2663.
4. Kalow W. Familial incidence of low pseudocholinesterase level [letter]. Lancet. 1956;2:576-577.
5. Kalow W, Gunn DR. The relationship between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther. 1957; 120:203-214.
6. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers. Can J Biochem Physiol (Ottawa). 1957;35:339-346.
7. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase as indicated by dibucaine numbers. Can J Biochem Physiol. 1957;35:1305-1320.
8. Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL. Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987;262:549-557.
9. McGuire MC, Nogueira CP, Bartels CF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sei U S A. 1989;86:953-957.
10. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev. 1985;37:25-79.
11. Lunde PK, Frislid K, Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet. 1977;2:182-197.
12. Lin KM, Poland RE, Wan YJ, Smith MW, Lesser IM. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull. 1996;32:205-217.
13. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 1997'; 43:254-266.
14. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997:37:269-296.
15. Hasler JA, Estabrook R, Murray M, et al. Pharmacogenetics of cytochromes P450. Mo! Aspects Med. \999;20:12-137.
16. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
17. Lessard É, Hamelin B A, Labbé L, O'Hara G, Bélanger PM, Turgeon J. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999;9:683-696.
18. Lessard É, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-443.
19. Athanassiadis D, Cranston WI, Juel-Jensen BE, Oliver DO. Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure. BMJ. 1966;2:732-735.
20. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;2:584586.
21. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sei USA. 1993;90: 11825-11829.
22. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit. 1989; 11:415-420.
23. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet. 1993;341:63.
24. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353: 717-719.
25. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998; 129:1027-1030.
26. Furuta T, Ohashi K, Kosuge K, et al. C YP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65:552-561.
27. Helsby NA, Ward SA, Howells RE, Breckenridge AM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol. 1990;30:287-291.
28. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenbridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. Br J Clin Pharmacol. 1991;31:689-692.
29. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995;5:335-346.
30. Bluhm RE, Wilkinson GR, Shelton R, Branch RA. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther. 1993;53:89-95.
31. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt). 1999;13(7, suppl 3): 17-21.
32. Perry HM Jr, Tan EM, Carmody S, Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970;76:114-125.
33. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol. 1997;8:1049-1051.
34. Layton MA, Jones PW, Alldersea JE, et al. The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Rheumatology (Oxford). 1999;38:43-47.
35. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;! 19:985-989.
36. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter]. Lancet. 1993;341:1151.
37. Haas M, Yilmaz N, Schmidt A, et al, Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Kidney Blood Press Res. 1998;21:66-69.
38. Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ. 1996;313:591-594.
39. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensinconverting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial: EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 1998;47:1507-1511.
40. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin PharmacolTher. 1999;65:519-525.
41. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996;217:177-178.
42. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. ProcNatlAcadSei USA. 2000;97:34733478.
43. Beutler E. G6PD deficiency. Blood. 1994;84:3613-3636.
44. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sei USA. 1995;92:12260-12264.
45. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalane M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
46. Philip I, Plantefeve G, Vuillaumier-Barrot S, et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation. 1999;99:3096-3098.
47. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999;9:591-599.
48. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
49. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
50. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet. 1982;20:637-658.
51. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992;2:148-159.
52. Alves S, Prata MJ, Ferreira F, Amorim A. Thiopurine methyltransferase pharmacogenetics: alternative molecular diagnosis and preliminary data from Northern Portugal. Pharmacogenetics. 1999; 9:257-261.
53. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999; 16:342-349.
54. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotyperelated efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther. 1999;66:528-534.
55. Aoyama N, Tanigawara Y, Kita T, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori
56. eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol. 1999;34(suppl ll):80-83.
57. Furuta T, Ohashi K, Kobayashi K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther. 1999;66:265-274.
58. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the 2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Glyl6 correlates with the nocturnal phenotype. J Clin Invest. 1995;95:1635-1641.
59. Hall IP. 2 Adrenoreceptor polymorphisms: are they clinically important? Thorax. 1996;51:351 -353.
60. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the 2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997; 100:3184-3188.
61. Tan S, Hall IP. Dewar J, Dow E, Lipworth B. Association between 2-adrenoreceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997;350:995-999.
62. Flaum M, Lung CL. Tinkelman D. Take control of high-cost asthma. J Asthma. 1997;34:5-14.
63. Collins FS. Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med. 1999;341:28-37.
64. Wallace RW. DNA on a chip: serving up the genome for diagnostics and research. Mol Med Today. 1997;3:384-389.
65. Kurian KM, Watson CJ, Wyllie AH. DNA chip technology. J Pathol. 1999; 187:267-271.
66. Persidis A. Biochips: an evolving clinical technology. Hasp Pract (Off Ed). 1999:34:67-68, 73-76. 83-85.
67. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994:266:66-71.
68. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994:343:692-695.
69. Wooster W, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2 [published correction appears in Nature. 1996;379:749]. Nature. 1995:378:789-792.
70. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science. 1991 ;253:49-53.
71. Coussens L, Yang-Feng TL. Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139.
72. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644-1646.
73. Stern DF, Heffernan PA, Weinberg RA. p 185. A product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986;6:1729-1740.
74. Slamon DJ. Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
75. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177182.
76. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neuoverexpressing metastatic breast cancer. Semin Oncol. 1999;26(4, suppl 12):78-83.
77. Shak S, Herceptin Multinational Investigator Study Group. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4, suppl 12):71-77.
78. Haseltine WA. Not quite pharmacogenomics [letter]. Nat Biotechnol. 1998; 16:1295.
79. Burt VL, Whelton P. Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey. 1988-1991. Hypertension. 1995:25:305-313.
80. The Sixth Report of the Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure [published correction appears in Arch Intern Med. 1998;! 58:573]. Arch Intern Med. 1997:157:2413-2446.
81. Xie HG. Kim RB, Stein CM, Gainer JV, Brown NJ, Wood AJ. alA-Adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics. 1999;9: 651-656.
82. Hoit BD. Suresh DP, Craft L, Walsh RA, Liggett SB. 2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J. 2000:139:537-542.
83. Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL. ACE (I/ D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998:98:2148-2153.